Targeting angiogenesis in cancer: clinical development of bevacizumab.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingThe Role of CC-Chemokines in the Regulation of AngiogenesisImage-based assessment of growth and signaling changes in cancer cells mediated by direct cell-cell contact.What is known about melatonin, chemotherapy and altered gene expression in breast cancerInhibitory effects of Lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action.Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma.Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancerRecurrent oral cancer: current and emerging therapeutic approaches.Mechanisms of drug inhibition of signalling molecules.Advances in paediatric cancer treatmentPhase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.Clinical implications for vascular endothelial growth factor in the lung: friend or foe?Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitorFunctional PET imaging in cancer drug development.Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.Investigational VEGF antagonists for psoriasis.Monoclonal antibodies based on hybridoma technology.Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review.Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs.Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells.Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.Genetic heterogeneity of skin microvasculature.HMGB1: A Promising Therapeutic Target for Prostate Cancer.Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.Ginsenoside Rg3 inhibits endothelial progenitor cell differentiation through attenuation of VEGF-dependent Akt/eNOS signaling.
P2860
Q22305863-D1F5D2F8-A465-4339-A83E-14D08E2F30AFQ27346895-708F35AF-1821-4C3D-8E9D-D42BCDAE841EQ28077024-2E1F3775-CCD9-4914-8339-68E40907E674Q33506105-0ACE7506-DF07-4861-9195-E477116E0FCAQ33597963-262C5D70-BF91-47F3-B44D-FAF684A7A37BQ34297956-4D24A87C-88E0-475C-BC20-8E07339D6485Q34450375-7C546EDD-17A2-48EE-9797-5C21F97F0518Q34450520-44647329-EE3D-41B1-A0CC-1EEE3AB6C4CEQ35781926-27575133-D58E-4B4E-99D3-BCED2CE79904Q36104744-4DF4256B-F832-4505-AEDF-EF7F5403D088Q36283038-FD96296E-CC17-4097-93CA-8842EDC5FFFBQ36488752-C0BBEB3F-0A7C-4CA3-9734-F7ACEE03FDF5Q36508630-240A4643-203E-4190-882C-8EB88660C300Q36614114-ADE7D90D-D73B-4616-A1F8-6538FEBF4207Q36625050-3CB7511D-AEB6-4296-B217-9FDC7BB4EC17Q36734939-9632006F-6E36-4A8E-B6EA-436DBB3CC6F0Q36768305-5EE91B2A-7E88-4425-A9AF-E4E7B964D40BQ36922576-57B5ED02-3F66-4A88-B032-3CCADCAD56B2Q36983306-E5C15A79-8B18-481F-842B-A7F28BD28B91Q37380366-2B4A1821-13B0-4B2E-A146-243F468BF6A2Q37482178-0D825347-6910-47C5-847D-056C8F6B9039Q37956733-EFA91DC2-6AA2-4920-B2CA-DCD9B86C4749Q38162972-99DAD15C-BA25-41A7-AC0B-6D06AD2D5753Q38174692-30761F63-81E9-49F7-AC12-4FCCF8E0B69CQ38728552-ADA4CE9C-BD0D-4352-83CC-91461FEE888AQ38990116-1401BC68-76DA-434B-9B4B-9ED240B19A71Q39375805-FE7C88EB-E48A-4D58-9236-2EB0D9C10AF2Q39381863-C1BCE992-FD58-47C2-BA9C-C1C4BCD2607FQ39747275-0053EE3C-2564-4CF3-8A8D-D078DC28369CQ40009642-FA4A89D1-02DE-4245-AFA8-DE5D300AB22DQ41136849-6D92399C-41AB-4BA3-B421-084C4328A6AAQ44071556-564B7A57-D2DB-4E35-94F6-A65F6435245DQ50593803-FAA0F6EB-DBAC-4530-AA4B-5DB9C87EA0F9
P2860
Targeting angiogenesis in cancer: clinical development of bevacizumab.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@ast
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@en
type
label
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@ast
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@en
prefLabel
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@ast
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@en
P2860
P356
P1476
Targeting angiogenesis in cancer: clinical development of bevacizumab.
@en
P2093
David J Kerr
P2860
P356
10.1038/NCPONC0026
P577
2004-11-01T00:00:00Z